Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation

Katy Wright, Mandy D. Winkler, Braeden D. Newton, Maria Pia Sormani, Darin T. Okuda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To examine the temporal profile of absolute and lymphocyte subset data from dimethyl fumarate (DMF) start and relationships to disease behavior. Methods: A retrospective study performed on patients with an existing diagnosis of MS and a history of DMF exposure from a single MS center. Demographic, laboratory, and corresponding clinical relapse and MRI data were recorded from baseline and in 3-4-month intervals after treatment initiation extending to 3 years. The Spearman rank coefficient and mixed-effects models were used to assess longitudinal correlations between cell counts and measures of disease activity. Results: A total of 292 patients with MS (228 women; median age at DMF initiation: 40.6 years, range: 16.1-66.7 years) were identified. An increased risk of disease activity was associated with higher absolute lymphocyte count (ALC) values at 3 months (p = 0.001, OR: 1.82) and at 6 months (p = 0.032, hazard ratio: 1.73). A reduced risk of disease evolution in patients with lower ALC values < 1,200 cells/L compared with midtier (1,210-1,800 cells/L) and the highest tertile (>1,810 cells/L) was observed (p = 0.01). Conclusions: Reductions in ALC values at months 3 and 6 after treatment initiation appear to be associated with improved clinical and radiologic outcomes. These data alone may help to provide a better understanding of both the safety and efficacy of DMF.

Original languageEnglish (US)
Article numbere397
JournalNeurology: Neuroimmunology and NeuroInflammation
Volume4
Issue number6
DOIs
StatePublished - Oct 23 2017

Fingerprint

Lymphocyte Count
Lymphocyte Subsets
Retrospective Studies
Cell Count
Demography
Safety
Recurrence
Dimethyl Fumarate
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation. / Wright, Katy; Winkler, Mandy D.; Newton, Braeden D.; Sormani, Maria Pia; Okuda, Darin T.

In: Neurology: Neuroimmunology and NeuroInflammation, Vol. 4, No. 6, e397, 23.10.2017.

Research output: Contribution to journalArticle

Wright, Katy ; Winkler, Mandy D. ; Newton, Braeden D. ; Sormani, Maria Pia ; Okuda, Darin T. / Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation. In: Neurology: Neuroimmunology and NeuroInflammation. 2017 ; Vol. 4, No. 6.
@article{0a943556a7c9498b9138bb0440ac410e,
title = "Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation",
abstract = "Objective: To examine the temporal profile of absolute and lymphocyte subset data from dimethyl fumarate (DMF) start and relationships to disease behavior. Methods: A retrospective study performed on patients with an existing diagnosis of MS and a history of DMF exposure from a single MS center. Demographic, laboratory, and corresponding clinical relapse and MRI data were recorded from baseline and in 3-4-month intervals after treatment initiation extending to 3 years. The Spearman rank coefficient and mixed-effects models were used to assess longitudinal correlations between cell counts and measures of disease activity. Results: A total of 292 patients with MS (228 women; median age at DMF initiation: 40.6 years, range: 16.1-66.7 years) were identified. An increased risk of disease activity was associated with higher absolute lymphocyte count (ALC) values at 3 months (p = 0.001, OR: 1.82) and at 6 months (p = 0.032, hazard ratio: 1.73). A reduced risk of disease evolution in patients with lower ALC values < 1,200 cells/L compared with midtier (1,210-1,800 cells/L) and the highest tertile (>1,810 cells/L) was observed (p = 0.01). Conclusions: Reductions in ALC values at months 3 and 6 after treatment initiation appear to be associated with improved clinical and radiologic outcomes. These data alone may help to provide a better understanding of both the safety and efficacy of DMF.",
author = "Katy Wright and Winkler, {Mandy D.} and Newton, {Braeden D.} and Sormani, {Maria Pia} and Okuda, {Darin T.}",
year = "2017",
month = "10",
day = "23",
doi = "10.1212/NXI.0000000000000397",
language = "English (US)",
volume = "4",
journal = "Neurology: Neuroimmunology and NeuroInflammation",
issn = "2332-7812",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation

AU - Wright, Katy

AU - Winkler, Mandy D.

AU - Newton, Braeden D.

AU - Sormani, Maria Pia

AU - Okuda, Darin T.

PY - 2017/10/23

Y1 - 2017/10/23

N2 - Objective: To examine the temporal profile of absolute and lymphocyte subset data from dimethyl fumarate (DMF) start and relationships to disease behavior. Methods: A retrospective study performed on patients with an existing diagnosis of MS and a history of DMF exposure from a single MS center. Demographic, laboratory, and corresponding clinical relapse and MRI data were recorded from baseline and in 3-4-month intervals after treatment initiation extending to 3 years. The Spearman rank coefficient and mixed-effects models were used to assess longitudinal correlations between cell counts and measures of disease activity. Results: A total of 292 patients with MS (228 women; median age at DMF initiation: 40.6 years, range: 16.1-66.7 years) were identified. An increased risk of disease activity was associated with higher absolute lymphocyte count (ALC) values at 3 months (p = 0.001, OR: 1.82) and at 6 months (p = 0.032, hazard ratio: 1.73). A reduced risk of disease evolution in patients with lower ALC values < 1,200 cells/L compared with midtier (1,210-1,800 cells/L) and the highest tertile (>1,810 cells/L) was observed (p = 0.01). Conclusions: Reductions in ALC values at months 3 and 6 after treatment initiation appear to be associated with improved clinical and radiologic outcomes. These data alone may help to provide a better understanding of both the safety and efficacy of DMF.

AB - Objective: To examine the temporal profile of absolute and lymphocyte subset data from dimethyl fumarate (DMF) start and relationships to disease behavior. Methods: A retrospective study performed on patients with an existing diagnosis of MS and a history of DMF exposure from a single MS center. Demographic, laboratory, and corresponding clinical relapse and MRI data were recorded from baseline and in 3-4-month intervals after treatment initiation extending to 3 years. The Spearman rank coefficient and mixed-effects models were used to assess longitudinal correlations between cell counts and measures of disease activity. Results: A total of 292 patients with MS (228 women; median age at DMF initiation: 40.6 years, range: 16.1-66.7 years) were identified. An increased risk of disease activity was associated with higher absolute lymphocyte count (ALC) values at 3 months (p = 0.001, OR: 1.82) and at 6 months (p = 0.032, hazard ratio: 1.73). A reduced risk of disease evolution in patients with lower ALC values < 1,200 cells/L compared with midtier (1,210-1,800 cells/L) and the highest tertile (>1,810 cells/L) was observed (p = 0.01). Conclusions: Reductions in ALC values at months 3 and 6 after treatment initiation appear to be associated with improved clinical and radiologic outcomes. These data alone may help to provide a better understanding of both the safety and efficacy of DMF.

UR - http://www.scopus.com/inward/record.url?scp=85034014854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034014854&partnerID=8YFLogxK

U2 - 10.1212/NXI.0000000000000397

DO - 10.1212/NXI.0000000000000397

M3 - Article

VL - 4

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

SN - 2332-7812

IS - 6

M1 - e397

ER -